Inflammatory Bowel Disease: Symptoms, Early Diagnosis, and Advanced Treatments

Inflammatory bowel disease cases are rising across Latin America, climbing from 30 to 100 per 100,000 residents between 2012 and 2020 in Brazilian public health records published in a 2022 study in The Lancet Regional Health – Americas. La Nación reported that this group of chronic digestive disorders, which includes ulcerative colitis and Crohn’s disease, causes persistent diarrhea, abdominal pain, bleeding, and weight loss. While part of the growth stems from better recognition, physicians face major diagnostic hurdles because early symptoms mimic everyday stomach troubles.

Rising Prevalences and Diagnostic Delays in Latin America

Patients often wait to seek help because initial warning signs get mistaken for temporary infections or parasites. Symptoms lasting more than three or four weeks require clinicians to look beyond common bugs. Physicians frequently attribute chronic diarrhea or bleeding to amoebas rather than checking for chronic bowel inflammation. Juliao Baños, president of Pancco, noted that expanding medical infrastructure helps doctors evaluate persistent symptoms earlier.

Diagnostic workups can include tests for anemia, analysis of fecal calprotectin, and colonoscopies with biopsies when considered necessary. Raquel Analía González, coordinadora de la Unidad de Enfermedad Inflamatoria Intestinal del Instituto de Enfermedades Digestivas del Hospital Alemán, explained the urgency during the UEG Week conference in Barcelona.

Cuanto más temprano llegamos al diagnóstico, empezamos el tratamiento mucho más rápido y frenamos esa inflamación que tanto le afecta la calidad de vida al paciente.

Raquel Analía González

Advanced Biological Therapies and Persistent Treatment Challenges

Modern biological medications target specific inflammatory pathways to achieve sustained remission and heal the intestinal mucosa. Older options like corticosteroids reduce inflammation but carry heavy side effects and cannot manage chronic cases. Newer alternatives include anti-TNF drugs, integrin blockers, interleukin-23 inhibitors, and Janus kinase inhibitors. González pointed out that these targeted therapies give doctors more ways to control active disease.

Uncontrolled inflammation can cause bowel strictures, fistulas, and the need for surgery. Severe perianal Crohn’s disease often requires coordinated medical and surgical care to drain abscesses before starting biological agents. Long-term inflammation also raises colorectal cancer risks, making regular endoscopic monitoring essential after eight to ten years of disease progression.